43.42 -1.11 (-2.49%)
After hours: 5:00PM EDT
|Bid||30.86 x 800|
|Ask||54.00 x 900|
|Day's Range||43.71 - 44.91|
|52 Week Range||30.78 - 54.49|
|Beta (5Y Monthly)||1.36|
|PE Ratio (TTM)||33.99|
|Earnings Date||Jul 30, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||0.16 (0.37%)|
|Ex-Dividend Date||May 29, 2020|
|1y Target Est||40.27|
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
Bruker Introduces Breakthrough MALDI-2 Source on timsTOF fleX and Further Innovations in CCS-Enabled 4D Proteomics on timsTOF.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
Bruker's (BRKR) first-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.
Bruker (BRKR) delivered earnings and revenue surprises of -36.36% and -1.25%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Bruker Corporation (Nasdaq: BRKR) today announced the successful installation and customer acceptance of the world’s first Avance™ NEO 1.2 GHz NMR system at the CERM (www.cerm.unifi.it) of the University of Florence. CERM is an Italian center of the European research infrastructure in structural biology, called Instruct-ERIC.
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors is investigating possible violations of federal securities laws on behalf of investors of Bruker Corporation (“Bruker” or the “Company”) (BRKR). On February 18, 2020, Bruker disclosed that the Company’s Audit Committee “has initiated an internal investigation into an allegation recently received in connection with the year-end-close, primarily relating to income tax matters including the effective income tax rate for 2019 and the related income tax balance sheet accounts.”
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bruker Corporation - BRKR
Hagens Berman urges investors in Bruker Corporation (BRKR) who have suffered significant losses to submit their losses now. The firm is investigating possible securities law violations, and certain investors may have valuable claims. More specifically, Bruker and senior management have repeatedly assured investors that the Company’s internal controls over financial reporting are effective.
LOS ANGELES, CA / ACCESSWIRE / March 27, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bruker Corporation ("Bruker" or "the Company") (NASDAQ:BRKR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Law Offices of Frank R. Cruz continues its investigation on behalf of Bruker Corporation ("Bruker" or the "Company") (NASDAQ: BRKR) investors concerning the Company and its officers’ possible violations of federal securities laws.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Bruker Corporation.
LOS ANGELES, CA / ACCESSWIRE / March 26, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bruker Corporation ("Bruker" or "the Company") (NASDAQ:BRKR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bruker Corporation.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Bruker Corporation (BRKR) on Behalf of Investors
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Bruker Corporation (NASDAQ: BRKR) resulting from allegations that Bruker may have issued materially misleading business information to the investing public.